{"filings":[{"id":1333040,"accession_number":"0001730463-26-000072","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2026-06-29T20:03:35+00:00","items":["5.07"],"status":"ready","headline":"Autolus 2026 AGM passes all resolutions, re-elects directors and approves auditors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Adopted 2025 annual accounts: 165,846,326 for, 2,895,344 against.","Directors' remuneration report approved: 156,192,216 for, 12,502,946 against.","Ernst & Young LLP (US) reappointed as auditors for the 2026-2027 fiscal year.","Directors M Bonney, E Leiderman, and RW Azelby re-elected with strong majorities.","All six resolutions passed on a poll at the 2026 Annual General Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":927639,"accession_number":"0001730463-26-000069","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2026-06-09T11:30:05+00:00","items":["8.01","9.01"],"status":"ready","headline":"Autolus files UK annual report highlighting AUCATZYL launch, pipeline progress, and EU sales delay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AUCATZYL launched in US (Jan 2025) and UK (Jan 2026) for r/r B-ALL; conditional EU approval but no 2026 sales planned.","Obe-cel paediatric r/r B-ALL Phase 1b showed 95% ORR; Phase 2 enrollment expected complete H1 2027.","Obe-cel advanced to Phase 2 pivotal trial (LUMINA) for lupus nephritis; Phase 1 MS trial dosing started Oct 2025.","Manufacturing site Nucleus in Stevenage, UK; Cardinal Health 105 as US distribution partner.","AGM scheduled for June 29, 2026; ADS holders of record May 27, 2026 eligible to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77841,"accession_number":"0001730463-26-000058","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2026-05-14T11:53:38+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Autolus Q1 2026: AUCATZYL net revenue $26.2M; positive gross margin; reaffirms FY revenue $120-135M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $26.2M (vs $9.0M Q1 2025); gross profit $1.6M, first positive quarter for ALL business.","Net loss $71.6M ($0.27 loss per share); cash equivalents $229.4M, down from $300.7M at Dec 2025.","Reaffirms FY2026 AUCATZYL net product revenue guidance $120-135M; expects continued positive gross margin.","Cost reduction: ~13% workforce cut; annualized savings ~$15M starting 2027; restructuring charges ~$8M.","Clinical pipeline on track: pediatric ALL data end-2027; lupus nephritis data 2028; progressive MS initial data end-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95058,"accession_number":"0001193125-26-192362","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Autolus cuts workforce 13%; expects $8M restructuring charge, $15M annualized savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduces workforce ~13% as part of operational efficiency plan; impacted employees receive severance and benefits.","Expects total restructuring charges of ~$8M, primarily severance, recognized in H1 2026; plan substantially complete by Q3 2026.","Reaffirms FY 2026 AUCATZYL net product revenue guidance of $120M-$135M, up from $74M in 2025.","Expects ~$15M annualized cost savings beginning in 2027; aims for positive gross margin in 2026.","Clinical programs on track: CATULUS (pediatric ALL), LUMINA (lupus nephritis), BOBCAT (MS)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95057,"accession_number":"0001730463-26-000049","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Autolus Therapeutics dismisses EY UK and appoints EY US as independent auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed EY UK on April 14, 2026; no disagreements or reportable events in prior two fiscal years.","Audit committee appointed EY US as new independent auditor for FY 2026, effective immediately.","EY UK's audit reports for 2024 and 2025 were unqualified; prior material weakness in internal controls disclosed in Q1 2024 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95056,"accession_number":"0001730463-26-000043","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Autolus hosts ALL Business investor event; presentation lacks specific financial data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Virtual investor event held on April 8, 2026, titled 'Spotlight on the Acute Lymphoblastic Leukemia (ALL) Business'.","Presentation materials posted on company website and attached as Exhibit 99.1 to the 8-K filing.","Filed under Regulation FD; only cover slide and disclaimer visible in the provided exhibit text.","No new material financial, operational, or pipeline details are discernible from the filing content.","Event appears to be a strategic update; no guidance or quantitative disclosures included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107858,"accession_number":"0001730463-26-000032","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Autolus reports FY2025 AUCATZYL net revenue $74.3M; guides FY2026 $120-135M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 AUCATZYL net revenue $23.3M; full-year $74.3M, primarily from U.S. sales.","FY2025 net loss $287.5M ($1.08/share); cash & equivalents $300.7M at Dec 31.","FY2026 revenue guidance $120-135M; expects shift to positive gross margin in 2026.","UK launch commenced January 2026 after NICE evaluation; ROCCA real-world data confirm safety/efficacy.","Pipeline: initial obe-cel data in progressive MS (BOBCAT) and AL amyloidosis (ALARIC) expected YE 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107857,"accession_number":"0001730463-26-000019","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Autolus enters 10-year lentiviral vector supply deal with AGC Biologics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Master Service Agreement with AGC Biologics for lentiviral vector, critical for CAR-T production.","Minimum purchase: 14 batches in first 2 years; EUR 25 million over subsequent 5 years.","AGC granted first right to negotiate manufacturing of obe-cel (obecabtagene autoleucel).","10-year fixed term, non-exclusive; Autolus can terminate with certain fees, either party for default.","Agreement replaces prior arrangement; individual work orders govern specific projects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107856,"accession_number":"0001730463-26-000012","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Autolus reports preliminary 2025 AUCATZYL rev $75M; guides FY2026 $120-135M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited AUCATZYL net product revenue: Q4 2025 ~$24M, full year 2025 ~$75M.","FY 2026 revenue guidance $120M-$135M; expects positive gross margin in 2026.","Cash runway extended into Q4 2027 based on current operating plans.","Pipeline: obe-cel Phase 2 CATULUS (pediatric B-ALL) and LUMINA (lupus nephritis) enrolling; BOBCAT (MS) and AUTO8 (AL amyloidosis) first patients dosed.","UK commercial launch under NICE approval; manufacturing cost reduction initiatives underway."],"consensus_eps_estimate":-0.2716,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":75388000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124254,"accession_number":"0001730463-25-000095","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Autolus appoints former BioNTech CSO Ryan Richardson to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ryan Richardson appointed as Class I director effective Dec 1, 2025; served as BioNTech CSO (2018–2025).","Will receive £33,000 annual retainer and initial option grant for 80,000 ADSs at $1.41/ADS, vesting over 36 months.","Richardson led BioNTech's corporate strategy, capital markets, and multiple M&A deals.","Prior roles include Executive Director at J.P. Morgan Healthcare Investment Banking (2011–2018)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124253,"accession_number":"0001730463-25-000081","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Autolus Q3 net product revenue $21.1M; RMAT for pediatric ALL; lupus data show 83% remission","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 net product revenue of $21.1M and deferred revenue of $7.6M; net loss of $79.1M ($0.30 per share).","Cash, equivalents and marketable securities $367.4M at Sept 30, down from $588.0M at Dec 31, 2024.","FDA granted RMAT designation for obe-cel in pediatric r/r B-ALL; Phase 1 CATULUS data show 95% ORR.","Phase 1 CARLYSLE data in lupus nephritis: 83% DORIS remission, no ICANS/high-grade CRS; Phase 2 LUMINA start expected by year-end.","Leadership bolstered: Cintia Piccina US CCO, Miranda Neville CTO, Patrick McIlvenny CAO."],"consensus_eps_estimate":-0.2302,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":51099000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140933,"accession_number":"0001730463-25-000064","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Autolus reports Q2 AUCATZYL revenue $20.9M; EU/UK approvals secured but Germany launch on hold","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $20.9M in Q2, $29.9M H1 2025; 46 U.S. centers activated, >90% medical lives covered.","UK MHRA (Apr 25) and EC (Jul 17) conditional approvals granted for AUCATZYL in r/r B-ALL.","NICE preliminary ACD recommended against funding; EU launch paused, no sales expected in 2025-2026.","Cash $454.3M (Jun 30 vs $588.0M Dec 31); net loss $47.9M (Q2 2025) vs $58.3M (Q2 2024).","Pipeline: obe-cel Phase 2 LN trial and Phase 1 MS trial first patient dosing by year-end 2025."],"consensus_eps_estimate":-0.2404,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":29905000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158697,"accession_number":"0001730463-25-000046","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Autolus Therapeutics announces results of 2025 Annual General Meeting, all resolutions passed","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Resolution 1 (adopt 2024 accounts): 219,809,664 for, 97,503 against, 477,332 abstain.","Resolution 2 (approve directors' remuneration report): 216,036,710 for, 4,285,817 against.","Resolution 5 (re-elect Dr. R. Iannone as director): 199,042,000 for, 20,750,286 against.","Resolution 7 (approve Employee Share Purchase Plan with 3,000,000 shares): 219,651,874 for, 706,780 against.","All nine ordinary resolutions were duly passed on a poll."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158696,"accession_number":"0001730463-25-000043","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Autolus sets AGM for June 26; two directors to step down; new equity plan proposed","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["AGM on June 26, 2025; resolutions include adoption of 2024 accounts, auditor reappointment (EY LLP), and director re-elections.","Directors Joseph Anderson and Martin Murphy will not stand for re-election, ending their terms after the AGM.","New Employee Share Purchase Plan with Sharesave Sub-Plan (up to 3M shares) approved by Board on May 20, 2025, subject to shareholder approval.","Remuneration report and policy, plus re-election of Dr. Robert Iannone and Dr. Ravi Rao, also on the agenda."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158695,"accession_number":"0001193125-25-132111","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Autolus directors Anderson and Murphy will not stand for re-election at 2025 AGM","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph Anderson and Martin Murphy notified the board on May 23, 2025, of their decision.","Both directors stated the decision was not due to any disagreement with management or the board.","Their departure takes effect at the 2025 Annual General Meeting of Shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158694,"accession_number":"0001730463-25-000032","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Autolus reports Q1 AUCATZYL revenue $9.0M; UK MHRA approval for r/r B-ALL","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 AUCATZYL net product revenue $9.0M, first quarter of launch.","UK MHRA granted conditional marketing authorization for AUCATZYL in r/r B-ALL.","Net loss $70.2M ($0.26 per share) vs $52.7M ($0.24) in Q1 2024.","Cash & marketable securities $516.6M; company well-capitalized for launch and trials.","Phase 1 CARLYSLE data: 3/6 SLE patients complete renal response; Phase 2 LN trial by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":8982000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158693,"accession_number":"0001730463-25-000022","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Autolus schedules R&D investor event with corporate update; no specific data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate update presented at R&D investor event on April 23, 2025.","Presentation slides available on Autolus website after conclusion.","No financial results, pipeline updates, or guidance provided in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158692,"accession_number":"0001193125-25-072356","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Autolus Therapeutics VP Finance resigns; CFO Dolski appointed PAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Mercieca resigned as VP Finance & PAO on Feb 24, 2025, effective August 2025; not due to any disagreement.","CFO Rob Dolski appointed principal accounting officer effective April 3, 2025, in addition to his CFO role.","No additional compensation for Dolski for the added PAO duties; no family or transaction disclosures.","Mercieca's resignation follows a statutory three-month minimum notice period under UK law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177082,"accession_number":"0001730463-25-000010","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Autolus reports FY2024 net loss $220.7M; AUCATZYL launch on track with 33 U.S. centers","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $220.7M ($0.86 per share) vs $208.4M ($1.20) in 2023; revenue $10.1M (up from $1.7M).","Cash and marketable securities $588M at Dec 31, 2024, up from $239.6M, boosted by BioNTech deal and equity financing.","AUCATZYL commercial launch: 33 authorized treatment centers (covering ~60% of target U.S. patients); targeting 60 by end-2025.","Obe-cel under EMA/MHRA review with decisions expected H2 2025; Phase 1 SLE trial fully enrolled (6 patients), data at April R&D event.","BioNTech option for AUTO1/22 expired Feb 8, 2025, not exercised; Blackstone $30M milestone payment triggered by FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177081,"accession_number":"0001730463-25-000004","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Autolus presents at JPM Health Conference; no material news in 8-K","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Autolus presented corporate update at J.P. Morgan Health Conference on Jan 13, 2025.","Exhibit 99.1 slides attached to 8-K are truncated; full content not disclosed.","No financial, clinical, or strategic specifics can be extracted from this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193857,"accession_number":"0001730463-24-000132","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Autolus Therapeutics Q3 net loss $82M; FDA approval of AUCATZYL triggers $30M milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA approved AUCATZYL (obe-cel) for adult r/r B-ALL on Nov 8, 2024, ahead of PDUFA date.","FDA approval triggers $30M milestone payment from Blackstone to Autolus.","Cash and equivalents totaled $657.1M at Sep 30, 2024, up from $239.6M at Dec 31, 2023.","Net loss of $82.1M for Q3 2024 vs $45.8M in Q3 2023; diluted EPS -$0.31.","Matthias Will M.D. appointed Chief Development Officer effective Sep 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":10091000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193856,"accession_number":"0001730463-24-000129","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA approves Autolus' AUCATZYL (obe-cel) for adult r/r B-ALL; no REMS required","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Approval based on FELIX trial: 63% overall complete remission (CR/CRi) in efficacy-evaluable patients (n=65); median DOR 14.1 months.","Only 3% Grade ≥3 CRS and 7% Grade ≥3 ICANS; no REMS program required by FDA.","Boxed warning for CRS, neurologic toxicities, secondary hematological malignancies; T-cell malignancies risk noted.","Commercial manufacturing at Nucleus in Stevenage, UK; Cardinal Health as U.S. distribution partner.","EU and UK MAAs under review; company to host conference call Nov 11."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210196,"accession_number":"0001730463-24-000110","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Autolus presents corporate update at KBC Life Sciences Conference; limited exhibit provided","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation made at KBC Life Sciences Conference on September 26, 2024.","Presentation slides posted to company website; only title slide text available in the filing's exhibit.","Filing does not disclose new financial, clinical, or strategic information beyond prior disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210195,"accession_number":"0001730463-24-000104","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Autolus Therapeutics appoints Matthias Will, M.D. as Chief Development Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Will joins as CDO effective September 30, 2024.","Previously CMO at Dren Bio and VP Clinical Development at CRISPR Therapeutics.","Will lead development organization, including obe-cel for relapsed/refractory adult B-ALL.","Appointment comes as Autolus prepares to commercialize first product obe-cel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210194,"accession_number":"0001730463-24-000099","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Autolus secures up to £18.5M landlord funding for Nucleus facility clean rooms","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Landlord provides up to £18.5M for improvements to Stevenage manufacturing facility.","Annual rent will increase by ~£1.84M after improvements, capped at £2.19M.","Lease term unchanged through September 2043.","Amendments approved by audit committee due to director's familial relationship with landlord's parent executive."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210193,"accession_number":"0001730463-24-000088","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Autolus Q2 net loss $58.3M; cash $705.9M; obe-cel PDUFA Nov 16, 2024 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $58.3M ($0.22/sh) vs $45.6M ($0.26/sh) in Q2 2023; cash $705.9M up from $239.6M at Dec 31, 2023.","Obe-cel PDUFA target action date set at November 16, 2024; BLA under review by FDA.","FELIX data (median follow-up 21 mos): 40% of responders in ongoing remission without subsequent stem cell transplant.","MAA submitted to UK MHRA July 2024; EMA MAA accepted April 2024.","R&D expenses $36.6M, G&A $21.9M, both up on pre-commercialization activities and new manufacturing facility."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":10091000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228462,"accession_number":"0001730463-24-000076","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Autolus Therapeutics shareholders approve all nine resolutions at 2024 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Adoption of 2023 annual accounts passed with 190.78M votes for, 35.8K against.","Directors' remuneration report approved: 167.10M for, 23.69M against.","Ernst & Young LLP reappointed as auditors for the coming year.","All four director re-elections passed: Bain (99.52%), Butitta (98.36%), Itin (99.83%), Young (99.12%).","Board authorized to allot shares up to $8,400 nominal value (Resolution 8) and disapply pre-emption rights (Resolution 9)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228461,"accession_number":"0001730463-24-000074","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Autolus publishes UK Annual Report; provides obe-cel BLA status, PDUFA date Nov 16, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BLA for obe-cel accepted by FDA; PDUFA target action date set for 16 November 2024.","Phase 2 FELIX study data: 78% CR/CRi rate in evaluable r/r adult B-ALL patients; median follow-up 16.6 months.","First two patients enrolled in CARLYSLE Phase 1 trial of obe-cel for SLE; initial data expected by end of 2024.","In Phase 1 ALLCAR19 trial, 41% of patients in ongoing remission at 3-year median follow-up without transplant.","AUTO1/22 dual-targeting CAR T showed 83% MRD-negative complete remission in paediatric r/r B-ALL."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228460,"accession_number":"0001730463-24-000070","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Autolus presents FELIX update: 78% ORR, 40% ongoing remission without SCT, median OS 23.8 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR 78% (99/127); median EFS 11.9 months, median OS 23.8 months; 12-month OS rate 61.1%.","40% of responders in ongoing remission without SCT or other therapy at median 21.3 months follow-up.","Ongoing CAR T persistence associated with 2.7x lower relapse/death risk vs. loss of persistence.","Consolidative SCT after obe-cel did not appear to improve EFS or OS in responders.","BLA under FDA review with PDUFA target action date November 16, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228459,"accession_number":"0001730463-24-000059","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Autolus reports Q1 2024 net loss of $52.7M; cash $758.5M; obe-cel PDUFA Nov 16","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $52.7M ($0.24 diluted EPS) vs $39.8M loss year ago; license revenue $10.1M.","Cash $758.5M at March 31, 2024, up from $239.6M Dec 31, after $350M offering and BioNTech financing.","Obe-cel BLA under FDA review; PDUFA target action date Nov 16, 2024; MAA accepted by EMA.","First two patients enrolled in SLE Phase 1 (CARLYSLE); initial data expected end of 2024.","BioNTech strategic collaboration ($50M upfront, up to $582M milestones) and $200M private placement; Mike Bonney appointed Chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":10091000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228458,"accession_number":"0001193125-24-136696","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Autolus Therapeutics delays Q1 2024 filing; cancels May 14 earnings call, reschedules to May 17","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plans to file Form 12b-25 for automatic 5-day extension of Q1 2024 10-Q due May 15.","Cancels previously announced earnings call scheduled for May 14, 2024.","Reschedules Q1 2024 conference call and webcast to May 17, 2024 at 8:30 am EDT.","Expects to file Q1 10-Q no later than May 20, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228457,"accession_number":"0001730463-24-000050","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Autolus appoints Mike Bonney as Chair and Ravi Rao as director; John Johnson resigns effective April 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John H. Johnson steps down as Chairman and Non-Executive Director; departure not due to disagreements.","Mike Bonney appointed Chairman of the Board; over 30 years biotech experience, formerly CEO of Cubist Pharmaceuticals.","Ravi Rao, M.D. appointed Non-Executive Director; current CMO of Sitryx and previous CMO at Oxford Biomedica.","Board changes effective April 1, 2024; Bonney and Rao receive annual retainers and initial option awards.","Press release notes recent FDA acceptance of BLA for obe-cel in r/r adult B-cell ALL as key company milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247142,"accession_number":"0001730463-24-000045","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Autolus restates 2021-2022 financials on R&D tax credit classification error","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Error: UK SME R&D tax credits previously classified as income tax benefit should reduce R&D expense instead.","Audit committee concluded non-reliance on FY2021 and FY2022 annual and interim financial statements on March 15, 2024.","Restatement reduces income tax benefit by $24.6M (2022) and $24.0M (2021), with offsetting cuts to R&D expense; net loss unchanged.","Company will correct error in upcoming 10-K for FY2023; no prior filings will be amended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247135,"accession_number":"0001730463-24-000029","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K/A","filed_at":"2024-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Autolus files 8-K/A to furnish Q4 2023 earnings call transcript; no new financial details","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Amendment filed solely to furnish transcript of March 14, 2024 FY2023 earnings call.","The transcript does not contain specific financial data (revenue, EPS, etc.).","Original 8-K with press release remains the source for actual financial results.","No substantive changes were made to the previously filed financial information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247141,"accession_number":"0001730463-24-000021","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Autolus FY2023 net loss $208.4M; raises $600M via BioNTech deal and offering; CDO resigns","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2023 was $208.4M ($1.20 diluted EPS) vs $148.8M in 2022; cash at year-end $239.6M.","In Feb 2024, closed BioNTech collaboration ($250M upfront) and $350M ADS offering for $600M gross proceeds to fund obe-cel launch.","BLA for obe-cel in r/r adult B-ALL submitted to FDA; PDUFA target action date Nov 16, 2024; MAA submitted to EMA.","CDO Dr. Edgar Braendle resigns effective March 2024; will consult. Chris Williams promoted to CBO, Alex Driggs to SVP Legal.","Obe-cel Phase 1 SLE trial open for enrollment; initial data expected late 2024; Nucleus manufacturing facility obtained MIA for commercial supply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247140,"accession_number":"0001193125-24-033690","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Autolus posts updated corporate presentation; no material new details available","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company posted updated corporate presentation to its website on February 13, 2024.","Presentation titled 'Developing Next Generation Programmed T Cell Therapies' (February 2024).","Filing and appended exhibit do not disclose specific financial or operational updates.","No changes to guidance, pipeline status, or material events reported in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247139,"accession_number":"0001193125-24-028372","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Autolus prices $350M ADS offering at $6.00 per ADS for obe-cel development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 58,333,336 ADSs at $6.00/ADS for gross proceeds of $350 million.","Net proceeds to fund obe-cel clinical development, manufacturing, and commercial infrastructure.","Additionally expects $250 million from BioNTech under license/option agreement and private placement.","Offering expected to close February 12, 2024; Jefferies and Truist are joint bookrunners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247138,"accession_number":"0001193125-24-027393","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Autolus enters $200M equity deal and strategic CAR-T collaboration with BioNTech","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["BioNTech invests $200M in Autolus ADS at $6.00 per share, plus $50M upfront under license agreement.","Autolus grants BioNTech exclusive license to certain binders; total potential milestones up to $582M.","BioNTech gets rights to use Autolus' UK manufacturing capacity to accelerate BNT211 into pivotal trials.","BioNTech receives up to mid-single-digit royalty on obe-cel net sales; Autolus retains full control of obe-cel.","BioNTech gains option to co-commercialize AUTO1/22 and AUTO6NG and a board nomination right."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247137,"accession_number":"0001730463-24-000007","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-01-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Autolus Therapeutics announces FDA acceptance of BLA for obe-cel; PDUFA date Nov 16, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted BLA for obe-cel in relapsed/refractory Adult B-ALL; PDUFA target action date November 16, 2024.","No advisory committee meeting is currently planned for this application.","BLA submission based on Phase 2 FELIX study data presented at ASCO 2023 and ASH 2023.","Company plans to submit Marketing Authorization Application to EMA in H1 2024.","Obe-cel has Orphan Drug, RMAT (FDA), and PRIME (EMA) designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247136,"accession_number":"0001730463-24-000004","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Autolus appoints Robert Azelby to Board, commercial focus as BLA for obe-cel submitted","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert W. Azelby appointed Class II director effective Jan 9, 2024; brings 30+ years biopharma commercial experience.","Initial option grant of 80,000 ADSs at $6.84/share; annual retainer £52,500 plus £3,500 for committee service.","Azelby was CEO of Eliem Therapeutics and Alder BioPharmaceuticals; served at Juno and Amgen.","Company recently submitted BLA for lead CAR T therapy obe-cel; Azelby to aid commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264579,"accession_number":"0001730463-23-000125","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Autolus appoints Elisabeth Leiderman to board; Kapil Dhingra resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kapil Dhingra resigned from Board effective Dec 31, 2023; not due to any disagreement with company.","Elisabeth Leiderman appointed as Class II director effective Dec 20, 2023; will serve on Audit Committee.","Leiderman receives £52,500 annual retainer, £6,500 audit committee retainer, and option to purchase 80,000 ADSs at $5.50.","Leiderman most recently CFO/CBO of Atsena Therapeutics; also serves on bluebird bio board.","Press release also notes BLA submission for obe-cel in r/r adult B-ALL to FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264578,"accession_number":"0001730463-23-000119","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Autolus obe-cel FELIX pooled analysis: 78% CR/CRi, 12-mo EFS 50%, low immunotoxicity; BLA filed for r/r B-ALL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pooled FELIX Phase Ib/II (n=127): CR/CRi rate 78%; grade ≥3 CRS 2%, ICANS 7%; median follow-up 16.6 months.","Patients with <5% BM blasts at lymphodepletion: 12-mo EFS 65%, no grade ≥3 CRS or ICANS (n=36).","Pooled ALLCAR19/FELIX Ib (n=36) in r/r B-ALL: 81% remission rate; 41% in ongoing CR at median >3 years follow-up without transplant.","AUTO8 (BCMA/CD19 dual CAR) MCARTY Phase I (n=11): 100% ORR, 7 CR/sCR, no grade ≥3 CRS/ICANS; trial enrolling.","BLA for obe-cel in relapsed/refractory adult B-ALL submitted to FDA; ASH data support regulatory filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264577,"accession_number":"0001730463-23-000115","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Autolus submits BLA to FDA for cell therapy obe-cel in r/r adult B-ALL","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["BLA for obecabtagene autoleucel (obe-cel) submitted to FDA for relapsed/refractory adult B-cell ALL.","Submission based on Phase 2 FELIX study data presented at ASCO 2023; updated data at ASH December 2023.","Autolus on track to submit Marketing Authorization Application to EMA in H1 2024.","Obe-cel has FDA Orphan Drug, RMAT, and EMA PRIME designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264576,"accession_number":"0001730463-23-000106","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Autolus voluntarily elects U.S. domestic issuer reporting, no change to Q3 2023 financials","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Autolus will file periodic reports on Forms 10-K, 10-Q, and 8-K instead of foreign private issuer forms.","No financial or disclosure changes from the Form 6-K filed on November 2, 2023 for the quarter ended September 30, 2023.","Company retains foreign private issuer status, exempt from U.S. proxy rules, Regulation FD, and Section 16.","Effective immediately; first U.S. domestic issuer report to be filed later today (Q3 2023 Form 10-Q)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":447141707.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}